A NEW APPROACH TO TREATING OBESITY: INTEGRATING ADVANCED PHARMACOTHERAPY AND METABOLIC SURGERY IN A PERSONALISED TREATMENT ALGORITHM
Abstract
Background: Obesity management will need new approaches as opposed to traditional approaches that are often ineffective. The review will bring together current available evidence on the advanced pharmacotherapy and metabolic surgery to mend this treatment gap.
Methods: PubMed, Scopus, and Web of Science (2020-2024) were used to search for and find a narrative review. These trials, meta-analyses, and consensus publications on GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and metabolic interventions (e.g., gastric bypass, sleeve gastrectomy) were combined and analyzed by us.
Results: New pharmacotherapies increase weight loss by 1522 per weight loss, matching the effect of surgical procedures and providing a wide range of cardiometabolic advantages. Yet, on discontinuation, weight regain is expected. Metabolic surgery is the most permanent operation, and it maintains weight reduction of 25-35 per cent for more than 10 years and determines significant remission of type 2 diabetes. The two modalities are complementary in that pharmacotherapy offers a definitive solution that is scalable and reversible, whereas surgery offers a definitive physiological solution. We combine these results and come up with a personalised algorithm of treatment that incorporates both of them, depending on the severity of the disease and the factors related to the patient.
Conclusion: The future of effective and individualized management of obesity relies on an integrated and chronic care model that should be deployed in the pharmacotherapy and surgery combination in a synergistic way.
References
Alqatari, S. G., Alwaheed, A. J., Hasan, M. A., Argan, A., Alabdullah, M. M., Al, M. D., Alqahtani, M. S., Alghamdi, A. S., Alzahrani, M. A., Alghamdi, F. S., Alomari, S. O., Alahmadi, Y. M., Alharbi, A. G., Aljohani, N. J., Alrashed, M. A., Alshahrani, A. M., Alshehri, A. A., Alzahrani, A. S., ... Al-Noshokaty, T. M. (2025). Pharmacologic disruption: How emerging weight loss therapies are challenging bariatric surgery guidelines. Medicina, 61(7), 1292. https://doi.org/10.3390/medicina61071292
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Elshafei, M. N., Elshanwany, A. A., Fathy, M., Ibrahim, M. A., Kassem, M. A., Khalil, M. A., Metwally, A. M., Mohamed, A. A., Mostafa, A. M., Omar, M. A., Saad, M. A., Salem, M. A., ... Zaki, M. A. (2025). Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential. Toxicology Reports, 14, 101895. https://doi.org/10.1016/j.toxrep.2025.101895
Andrade, S., Lobato, C. B., Machado, M., Hartmann, B., Holst, J. J., Almeida, R. F., & Carvalho, P. (2025). GLP-1 and GIP may play a role in long-term weight trajectories after gastric bypass. Frontiers in Endocrinology, 16, [Article in Press]. https://doi.org/10.3389/fendo.2025.1624001
Brown, W. A., Brown, D. L., Holland, J. F., Campbell, A., Cottrell, J., Ahern, S., & Gauri, A. (2025). Metabolic bariatric surgery generates substantial, sustained weight loss and health improvement in a real‐world setting. ANZ Journal of Surgery, 95(5), 895–903. https://doi.org/10.1111/ans.19378
Butt, M. D., Ong, S. C., Rafiq, A., Kalam, M. N., Sajjad, A., Abdullah, M., & Khan, A. H. (2024). A systematic review of the economic burden of diabetes mellitus: Contrasting perspectives from high and low middle-income countries. Journal of Pharmaceutical Policy and Practice, 17(1), [Article in Press]. https://doi.org/10.1080/20523211.2024.2322107
Cohen, R. V., Busetto, L., Levinson, R., Roux, L., Salminen, P., Prager, G., & Sarr, M. (2024). International consensus position statement on the role of obesity management medications in the context of metabolic bariatric surgery: Expert guideline by the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). British Journal of Surgery, 111(12), znae288. https://doi.org/10.1093/bjs/znae283
Coutinho, W., & Halpern, B. (2024). Pharmacotherapy for obesity: Moving towards efficacy improvement. Diabetology & Metabolic Syndrome, 16(1), 2. https://doi.org/10.1186/s13098-023-01233-4
Dowgiałło-Gornowicz, N., Jaworski, P., Orłowski, M., Franczak, P., Proczko-Stepaniak, M., Kloczkowska, A., & Łaski, D. (2025). Long-term outcomes of metabolic bariatric surgery: A 10-Year multicenter retrospective study in Poland (BARI-10-POL). Langenbeck's Archives of Surgery, 410(1), [Article in Press]. https://doi.org/10.1007/s00423-025-03713-9
Doycheva, I., & Ehrmann, D. A. (2022). Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertility and Sterility, 117(5), 897–911. https://doi.org/10.1016/j.fertnstert.2022.03.020
Kermansaravi, M., Rohollah Valizadeh, Masoumeh Shahsavan, Seyyed Adel Maleknia, Eghbali, F., Abdolreza Pazouki, & Shahab Shahabi Shahmiri. (2024). Metabolic and bariatric surgery in patients with class I obesity; a two-year follow-up. BMC Surgery, 24(1). https://doi.org/10.1186/s12893-023-02295-x
Kheniser, K., Saxon, D. R., & Kashyap, S. R. (2021). Long-term weight loss strategies for obesity. The Journal of Clinical Endocrinology & Metabolism, 106(7), e2814–e2821. https://doi.org/10.1210/clinem/dgab091
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023). Pharmacological support for the treatment of obesity—Present and future. Healthcare, 11(3), 433. https://doi.org/10.3390/healthcare11030433
Mousavi, A., Shojaei, S., Azarboo, A., Bahri, R. A., Mohammadi, S., Alilou, S., & Vajdi, M. (2025). The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: A systematic review and meta-analysis. *Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 30*(1), 92. https://doi.org/10.1007/s40519-025-01770-z
Noria, S. F., Shelby, R. D., Atkins, K. D., Nguyen, N. T., & Gadde, K. M. (2023). Weight regain after bariatric surgery: Scope of the problem, causes, prevention, and treatment. Current Diabetes Reports, 23(3), 31–42. https://doi.org/10.1007/s11892-023-01498-z
Nunns, M., Febrey, S., Buckland, J., Abbott, R., Whear, R., Bethel, A., & Thompson Coon, J. (2025). The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: A scoping review. Health Technology Assessment, 29, [Article in Press]. https://doi.org/10.3310/SKHT8119
Pipek, L. Z., Moraes, W. A. F., Nobetani, R. M., Cortez, V. S., Condi, A. S., Taba, J. V., & de Souza, R. K. (2024). Surgery is associated with better long-term outcomes than pharmacological treatment for obesity: A systematic review and meta-analysis. Scientific Reports, 14(1), 9521. https://doi.org/10.1038/s41598-024-57724-5
Przybyłowski, A., Górski, M., Gwioździk, W., & Polaniak, R. (2025). Redefining obesity: A narrative review of diagnostic evolution, therapeutic strategies and psychosocial determinants. Healthcare, 13(16), 1967. https://doi.org/10.3390/healthcare13161967
Roth, A. E., Thornley, C. J., & Blackstone, R. P. (2020). Outcomes in bariatric and metabolic surgery: An updated 5-year review. Current Obesity Reports, 9(3), 380–389. https://doi.org/10.1007/s13679-020-00389-8
Samuels, J. M., Ye, F., Irlmeier, R., Silver, H., Srivastava, G., & Spann, M. (2025). Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity and Metabolism, [Article in Press]. https://doi.org/10.1111/dom.70004
Sarma, S., & Palcu, P. (2022). Weight loss between glucagon‐like peptide‐1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and meta‐analysis. Obesity, 30(11), 2111–2121. https://doi.org/10.1002/oby.23563
Sokary, S., & Bawadi, H. (2025). The promise of tirzepatide: A narrative review of metabolic benefits. Primary Care Diabetes, 19(2), [Article in Press]. https://doi.org/10.1016/j.pcd.2025.03.008
Soliman, A. R., eldin, M., Hady, A., Naguib, M., Mohamed, R. S., Abdelaziz, G. R., & Elsherif, A. (2025). Metabolic/bariatric surgery optimization: A position statement by Arabic association for the study of diabetes and metabolism (AASD). Diabetology & Metabolic Syndrome, 17(1), 26. https://doi.org/10.1186/s13098-024-01564-w
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., & Ludwig, D. S. (2025). Novel strategies for medical management of obesity: Mechanisms, clinical implications, and societal impacts—a report from the 25th Annual Harvard Nutrition Obesity Symposium. The American Journal of Clinical Nutrition, 121(6), [Article in Press]. https://doi.org/10.1016/j.ajcnut.2025.06.015
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024). The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism, 159, 155957. https://doi.org/10.1016/j.metabol.2024.156057
Sutanto, A., Wungu, C. D. K., Susilo, H., & Sutanto, H. (2021). Reduction of major adverse cardiovascular events (MACE) after bariatric surgery in patients with obesity and cardiovascular diseases: A systematic review and meta-analysis. Nutrients, 13(10), 3568. https://doi.org/10.3390/nu13103568
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes, Obesity and Metabolism, 27(Suppl. 2), 66–88. https://doi.org/10.1111/dom.16364
Valdes, S., Vilarrasa, N., Rubio-Herrera, M. A., de Hollanda, A., & Area of Obesity of the Spanish Society of Endocrinology and Nutrition (Obesity SEEN). (2023). New IFSO/ASMBS indications for metabolic and bariatric surgery? Yes, after failure of best nonsurgical therapy. Obesity Surgery, 33(8), 2592–2593. https://doi.org/10.1007/s11695-023-06665-5
World Health Organization. (2025). Obesity and overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight
Xia, C., Wang, M., Lv, H., Li, M., Jiang, C., Liu, Z., & Wang, O. (2021). The safety and necessity of concomitant cholecystectomy during bariatric surgery in patients with obesity: A systematic review and meta-analysis. Obesity Surgery, 31(12), 5418–5426. https://doi.org/10.1007/s11695-021-05713-2
Copyright (c) 2025 Katarzyna Kleszczewska, Agnieszka Pruska, Natalia Senatorska, Julia Rarok, Daria Godlewska, Hanna Pietruszewska, Monika Banaszek, Agata Panfil, Julia Błocka, Agata Lurka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
